Vorinostat is a histone deacetylase inhibitor and causes growth arrest and death of some transformed cells both in vitro and in vivo, with little or no toxic effects on normal cells. Marks, P.A. "Discovery and development of SAHA as an anticancer agent." Oncogene 26: 1351-1356 (2007).
Vorinostat was studied in single agent trials and combination trials for patients with refractory cutaneous T cell lymphoma. Cang, S., et al. "New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer." J. Hematol. Oncol. 2: 22 (2009).
Vorinostat caused an accumulation of acetylated histones, p21(WAF1) and bax, a decrease of Stat6, and activation of caspase-3, and thus selectively induced malignant T cell apoptosis. Zhang, C., et al. "Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action." J. Invest. Dermatol. 125: 1045-1052 (2005).
Vorinostat improves tumor radioresponse. Munshi, A., et al. "Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci." Mol. Cancer Ther. 5: 1967-1974 (2006).
Vorinostat is the active ingredient in the drug sold under the trade name Zolinza®. This drug has been approved in at least one country for use in patients with cutaneous T cell lymphoma (CTCL) and Sézary syndrome, another type of lymphoma closely related to CTCL. NOTE: The vorinostat product sold by LC Laboratories is NOT Zolinza® and is NOT for human use.
Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
Not available in some countries; not available to some institutions; not available for some uses.
Soluble in DMSO at 66 mg/mL; soluble in ethanol at 2 mg/mL with slight warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solu
